Medcxy

Product dossierBuilt from registrations, label text and platform-curated data

凯乐普注射用修饰透明质酸钠凝胶

Ask about this product

凯乐普 is a Hyaluronic acid filler product (Class III device), registered by 山东凯乐普生物工程有限公司. Linked registrations: China 国械注准20243130343. Data as of 2026-10-23.

  • Regulatory classHyaluronic acid filler · Class III device
  • Holder山东凯乐普生物工程有限公司
  • JurisdictionsCN
  • Updated2026-10-23 · v1

Registration and basics are public; findings and prices need an account

Registration and basics

凯乐普

Product
Regulatory class
Class III device
Category
Hyaluronic acid filler
China · NMPA device registration
国械注准20243130343
Name on registration
注射用修饰透明质酸钠凝胶
Registrant
山东凯乐普生物工程有限公司
First approval
Not obtained from an official source
This certificate issued
2024-02-21
Valid until
2029-02-20
Models and sizes
0.5mL；0.75mL；1.0 mL；1.25mL；1.5 mL；2.0 mL
Checked against official page
2026-10-23

Public: fields from the registration record.

Label facts by jurisdiction

What each jurisdiction's label says for the same attribute; gaps are marked Not reported, irrelevant ones N/A

AttributeChina label
Storage规格型号 型号规格：2.0 mL 包装规格：2.0 mL×2：2～25℃保存，避免阳光照射和冷冻

Each cell is extracted from that jurisdiction's label; click the number for the original passage. “—” means nothing has been extracted for it yet, not that the label is silent. 1 of them are not yet reviewed by a person.

Registration timeline

  1. CN

    国械注准20243130343 this certificate issued

    Issue date of this certificate, not the first approval

  2. CN

    国械注准20243130343 valid until

First approval, this certificate's issue date (updated after renewals or changes), changes and expiry are listed separately; a missing first approval means it was not obtained from an official source. Up to 6 recent changes per registration; click the number for the full record.

Cross findings · Price observations

Sign in to see findings and prices

Findings and prices stay out of indexable pages.

Sign in to view

Recent changes

1
  • 国械注准20243130343: certificate issued2024-02-21

Sources

2